Akebia Therapeutics, Inc. AKBA
0.72 USD +0.01 (+2.06%)
Nov 3, 2026, 3:57 PM EST
0.7094 Day range 0.7474
0.542 52-week range 2.15
- YTD
- -55.09%
- 1 year
- -65.90%
Analyst view
Price target (mean) 5.50 +660.7% upside
Now 0.723
- Target (low)
- 4.00
- Target (mean)
- 5.50
- Target (high)
- 7.50
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 3
- 2 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.04 | -0.04 – -0.04 | 0.00 | 0.0% | 40.91M | -27.2% | 1 |
| Next quarter | -0.075 | -0.15 – 0.00 | -0.0843 | +11.0% | 35.61M | +9.2% | 2 |
| Current year | -0.26 | -0.26 – -0.26 | -0.2732 | +4.8% | 154.60M | -20.6% | 1 |
| Next year | -0.195 | -0.47 – 0.08 | -0.26 | +25.0% | 177.96M | +15.1% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 23, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 10, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 8, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 6, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 28, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 17, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 27, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 28, 2023 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| Aug 11, 2023 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Jun 21, 2023 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Jun 14, 2023 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Jun 2, 2023 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| May 31, 2023 | Piper Sandler | Upgrade | Neutral | Overweight |
| May 30, 2023 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| May 26, 2023 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| May 9, 2023 | Needham | Reiterated | — | Neutral |
| Apr 26, 2023 | HC Wainwright & Co. | Maintained | — | Neutral |
| Mar 31, 2023 | HC Wainwright & Co. | Reiterated | — | Neutral |
| Mar 10, 2023 | HC Wainwright & Co. | Reiterated | — | Neutral |
| Feb 22, 2023 | HC Wainwright & Co. | Maintained | — | Neutral |
| May 16, 2022 | HC Wainwright & Co. | Maintained | — | Neutral |
| Mar 31, 2022 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Mar 31, 2022 | Needham | Downgrade | Buy | Hold |
| Mar 31, 2022 | Mizuho | Downgrade | Buy | Neutral |
| Mar 31, 2022 | Piper Sandler | Downgrade | Overweight | Neutral |
| Nov 11, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Mar 8, 2021 | Cantor Fitzgerald | Initiated | — | Overweight |
| Mar 8, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
